784-P: Once-Weekly Semaglutide in Patients with Peripheral Arterial Disease and Type 2 Diabetes—Comorbidities and Concomitant Medications from the STRIDE Trial

Lower extremity peripheral arterial disease (PAD) is caused by atherosclerosis of leg arteries and may result in severe functional impairment. People with type 2 diabetes (T2D) are at higher risk of developing PAD than those without T2D. We present baseline data from STRIDE, a phase 3 trial investigating functional outcomes of semaglutide treatment in patients with PAD and T2D. STRIDE enrolled 792 patients with PAD (Fontaine IIa claudication) and T2D who were randomized to either 1 mg once-weekly subcutaneous semaglutide or placebo for 52 weeks. The primary outcome is change in maximum walking distance on a constant load treadmill. Baseline characteristics, comorbidities and medications were recorded. Median age was 68, 75.4% male, a median duration of T2D of 12 years, mean HbA1c 7.3% and LDL-C 2.0 mmol/L. CVD related history included: hypertension (87.9%), coronary disease (42.4%), coronary revascularization (31.4%), MI (18.7%), coronary artery stenosis >50% (27.5%), stroke (6.4%), transient ischemic attack (3.9%), chronic heart failure (13.6%), and chronic kidney disease (15.8%). More than a third were on SGLT2is. Baseline medications are shown in table 1. We highlight the high CVD burden and the baseline medications of patients in STRIDE, representing a study population with multiple comorbid risk factors and reasonably well controlled T2D.